Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00582712
Other study ID # CO07312
Secondary ID 2007-0195NCI-201
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 2008
Est. completion date April 2012

Study information

Verified date October 2016
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date April 2012
Est. primary completion date May 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed MTC with signs of residual/persistent disease based on tumor marker levels and/or radiographic imaging. Pathologic diagnosis must be confirmed at UWCCC. Grading must be confirmed by pathologic review performed at UWCCC.

- Elevated neuroendocrine markers at least 1 month post -op. In MTC, persistently elevated neuroendocrine markers such as calcitonin and CEA are indicative of persistent disease.

- Disease progression is not required for this trial

- 4 weeks from the completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration. Subjects will have had standard of care prior to enrollment. Subjects will have had standard of care prior to enrollment (for example it could include total thyroidectomy, central lymph node dissection, and when necessary ipsilateral radical neck dissection but is tailored to the patient).

- 3 weeks from the completion of radiation therapy to study registration

- The following laboratory values obtained within 14 days prior to registration:

- Absolute neutrophils count (ANC) = 1000/mm3

- Platelets = 75,000/mm3

- Hemoglobin = 8.0 g/dL

- Total bilirubin greater than or equal to 2.0 X the upper limit of normal (ULN)

- AST greater than or equal to 3 X ULN or greater than or equal to 5 X ULN if liver metastases are present

- Creatinine greater than or equal to ULN

- Serum sodium within normal limits

- ECOG performance status of 2

- Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

- Availability of tissue specimens to be analyzed for pathologic confirmation.

- Age = 18 years.

- Women must not be pregnant or lactating due to the deleterious effects of Lithium carbonate on a fetus or small child. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.

- Women of childbearing potential and sexually active males are required to use an accepted and effective method of contraception.

- Patients must not have known history of allergic reactions or adverse reactions to Lithium or its derivatives.

- Patients are not allowed to be on concurrent chemotherapy or radiation therapy.

Exclusion Criteria:

- Gastrointestinal tract disease resulting in an inability to take oral medication (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, bowel obstruction, or inability to swallow the tablets).

- Significant, active cardiac disease

- Patients must not be taking the following medications: diuretics, ACE inhibitors, NSAIDs (except aspirin or sulindac), neuroleptics, tetracycline, and COX2 inhibitors.

- Patients with radiographic evidence of disease will be presented the option to undergo a tumor biopsy although this is not mandatory.

- Patients already taking Lithium for any reason are not allowed on study

Study Design


Intervention

Drug:
Lithium carbonate
Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.

Locations

Country Name City State
United States Uniersity of Wisconsin Comprehensive Cancer Center Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03643055 - 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06277180 - 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC N/A
Withdrawn NCT04760288 - A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Phase 3
Not yet recruiting NCT06079723 - A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Recruiting NCT01739634 - The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Phase 1/Phase 2
Recruiting NCT03157128 - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Phase 1/Phase 2
Completed NCT02856347 - Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin N/A
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04280081 - A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Phase 2
Not yet recruiting NCT06292988 - Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Completed NCT01757470 - Vandetanib Risk Minimisation Effectiveness N/A
Recruiting NCT05830500 - Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma Phase 4
Recruiting NCT03899792 - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Phase 1/Phase 2
Recruiting NCT01660984 - Natural History Study of Children and Adults With Medullary Thyroid Cancer
Withdrawn NCT03838692 - Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer Phase 2
Terminated NCT02363647 - Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer N/A
Recruiting NCT06141369 - Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) N/A
Completed NCT06243965 - Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
Active, not recruiting NCT01298323 - Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Phase 3